Lai Wang Sells 470 Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Lai Wang sold 470 shares of the company’s stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $251.37, for a total transaction of $118,143.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Lai Wang also recently made the following trade(s):

• On Monday, June 16th, Lai Wang sold 1,177 shares of BeOne Medicines stock. The shares were sold at an average price of $266.40, for a total transaction of $313,552.80.
• On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The shares were sold at an average price of $252.39, for a total transaction of $353,850.78.

BeOne Medicines Stock Performance

NASDAQ ONC opened at $252.78 on Friday. The company has a fifty day moving average price of $245.25. The firm has a market cap of $27.69 billion, a PE ratio of -67.95 and a beta of 0.30. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $141.31 and a 52 week high of $287.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of ($0.71) by $1.93. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.12 billion. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. Equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on ONC shares. TD Securities reaffirmed a “buy” rating and set a $334.00 price objective on shares of BeOne Medicines in a research note on Thursday, April 24th. JMP Securities set a $348.00 price objective on shares of BeOne Medicines in a research note on Friday, February 28th. Wall Street Zen raised shares of BeOne Medicines from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. JPMorgan Chase & Co. upped their price objective on shares of BeOne Medicines from $311.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, April 21st. Finally, Bank of America raised shares of BeOne Medicines from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $319.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.